In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altana AG

www.altana.com

Latest From Altana AG

Appointments: Sanofi, Celgene, TeGenix, Allogene, Aimmune, TikoMed and Ionis Announce Changes At The Top

This week's appointments include a new CFO at Sanofi,  a new general counsel at Celgene plus new hires at TiGenix, Allogene Therapeutics, Aimmune Therapeutics, TikoMed and Ionis Pharmaceuticals, among others.

Appointments BioPharmaceutical

Deals Of The Week: New Remedies Sought From Nature And Old Technologies

Sanofi links with researchers at Germany’s Fraunhofer Gesellschaft in the search for new antibiotics while a European joint venture called Hit Discovery Constance GmbH is set up to conduct high-throughput screening for biotech and academic partners. Also, Moderna Therapeutics bags another major partner, GSK exits its DMD deal with Prosensa, and more.

BioPharmaceutical Europe

A Closer Look: Sun’s Settlement With Pfizer May Cloud Its Ability For Large Buyouts

With a large chunk of its cash reserves spent to settle the Protonix patent case, India’s Sun Pharma may no longer be in position to follow its inorganic growth plans.

BioPharmaceutical Asia Pacific

Takeda’s Strategic Run Up To Nycomed

With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.

BioPharmaceutical Business Strategies
See All

Company Information

UsernamePublicRestriction

Register